Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2013 | Research

Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study

Authors: Stamatina Iliodromiti, Vuong Thi Ngoc Lan, Ho Manh Tuong, Phung Huy Tuan, Peter Humaidan, Scott M Nelson

Published in: Journal of Ovarian Research | Issue 1/2013

Abstract

Background

Conventional luteal support packages are inadequate to facilitate a fresh transfer after GnRH agonist (GnRHa) trigger in patients at high risk of developing ovarian hyperstimulation syndrome (OHSS). By providing intensive luteal-phase support with oestradiol and progesterone satisfactory implantation rates can be sustained. The objective of this study was to assess the live-birth rate and incidence of OHSS after GnRHa trigger and intensive luteal steroid support compared to traditional hCG trigger and conventional luteal support in OHSS high risk Asian patients.

Methods

We conducted a retrospective cohort study of 363 women exposed to GnRHa triggering with intensive luteal support compared with 257 women exposed to conventional hCG triggering. Women at risk of OHSS were defined by ovarian response ≥15 follicles ≥12 mm on the day of the trigger.

Results

Live-birth rates were similar in both groups GnRHa vs hCG; 29.8% vs 29.2% (p = 0.69). One late onset severe OHSS case was observed in the GnRHa trigger group (0.3%) compared to 18 cases (7%) after hCG trigger.

Conclusions

GnRHa trigger combined with intensive luteal steroid support in this group of OHSS high risk Asian patients can facilitate fresh embryo transfer, however, in contrast to previous reports the occurrence of late onset OHSS was not completely eliminated.

Available only for authorised users

Itskovitz J, Erlik Y, Boldes R, Kahana L, Levron J, Brandes JM: Induction of preovulatory luteinizing-hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing-hormone agonist. Fertil Steril 1991, 56: 213–220.PubMed

Itskovitz-Eldor J, Kol S, Mannaerts B: Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000, 15: 1965–1968. 10.1093/humrep/15.9.1965PubMedCrossRef

Hoff JD, Quigley ME, Yen SSC: Hormonal dynamics at midcycle- a reevaluation. J Clin Endocrinol Metab 1983, 57: 792–796. 10.1210/jcem-57-4-792PubMedCrossRef

Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC: Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003, 88: 4186–4192. 10.1210/jc.2002-021953PubMedCrossRef

Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G: A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005, 20: 2887–2892. 10.1093/humrep/dei150PubMedCrossRef

Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY: GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005, 20: 1213–1220. 10.1093/humrep/deh765PubMedCrossRef

Pirard C, Donnez J, Loumaye E: GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006, 21: 1894–1900. 10.1093/humrep/del072PubMedCrossRef

Humaidan P, Bungum L, Bungum M, Andersen CY: Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006, 13: 173–178. 10.1016/S1472-6483(10)60612-8PubMedCrossRef

Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93: 847–854. 10.1016/j.fertnstert.2008.12.042PubMedCrossRef

10.

Humaidan P: Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009, 18: 630–634. 10.1016/S1472-6483(10)60006-5PubMedCrossRef

11.

Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY: GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013, 28: 2511–2521. 10.1093/humrep/det249PubMedCrossRef

12.

Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T: Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006, 21: 1260–1265. 10.1093/humrep/dei475PubMedCrossRef

13.

Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008, 89: 84–91. 10.1016/j.fertnstert.2007.02.002PubMedCrossRef

14.

Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C: Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011, 95: 2715–2717. 10.1016/j.fertnstert.2011.03.109PubMedCrossRef

15.

Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R: Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012, 27: 753–759. 10.1093/humrep/der463PubMedCrossRef

16.

Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24: 680–681. author reply 682–683 10.1016/j.rbmo.2012.03.005PubMedCrossRef

17.

Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L: Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril 2011, 96: 63–68. 10.1016/j.fertnstert.2011.04.050PubMedCrossRef

18.

Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A: Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011, 26: 1768–1774. 10.1093/humrep/der106PubMedCrossRef

19.

Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, Devroey P: Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003, 79: 873–880. 10.1016/S0015-0282(02)04920-8PubMedCrossRef

20.

Humaidan P, Quartarolo J, Papanikolaou EG: Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010, 94: 389–400. 10.1016/j.fertnstert.2010.03.028PubMedCrossRef

21.

RCOG: The management of ovarian hyperstimulation syndrome. London: Royal College of Obstetricians and Gynaecologists; 2006.

22.

Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12: 159–168.PubMedCrossRef

23.

Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, Khattab SM, Van Wely M: Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2011, 19: CD008046.

24.

Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K: The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013, 28: 1077–1083. 10.1093/humrep/det015PubMedCrossRef

25.

Humaidan P, Kol S, Papanikolaou EG: GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011, 17: 510–524. 10.1093/humupd/dmr008PubMedCrossRef

26.

Yovich JL, Stanger JD, Yovich JM, Tuvik AI, Turner SR: Hormonal profiles in the follicular phase, luteal phase and first trimester of pregnancies arising from in-vitro fertilization. Br J Obstet Gynaecol 1985, 92: 374–384. 10.1111/j.1471-0528.1985.tb01112.xPubMedCrossRef

27.

Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M: Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011, 5: CD009154.

28.

Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L: Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 2012, 97: 1316–1320. 10.1016/j.fertnstert.2012.03.015PubMedCrossRef

29.

Purcell K, Schembri M, Frazier LM, Rall MJ, Shen S, Croughan M, Grainger DA, Fujimoto VY: Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology. Fertil Steril 2007, 87: 297–302. 10.1016/j.fertnstert.2006.06.031PubMedCrossRef

30.

Huddleston HG, Rosen MP, Lamb JD, Modan A, Cedars MI, Fujimoto VY: Asian ethnicity in anonymous oocyte donors is associated with increased estradiol levels but comparable recipient pregnancy rates compared with Caucasians. Fertil Steril 2010, 94: 2059–2063. 10.1016/j.fertnstert.2009.11.019PubMedCrossRef

31.

Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S: Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 2011, 95: 2029-U2195. 10.1016/j.fertnstert.2011.01.163PubMedCrossRef

32.

Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod BioMed Online 2013, 26: 226–230. 10.1016/j.rbmo.2012.11.002PubMedCrossRef

33.

Mathur RS, Akande AV, Keay SD, Hung LP, Jenkins JM: Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000, 73: 901–907. 10.1016/S0015-0282(00)00492-1PubMedCrossRef

34.

Lawlor DA, Nelson SM: Effect of age on decisions about the numbers of embryos to transfer in assisted conception: a prospective study. Lancet 2012, 379: 521–527. 10.1016/S0140-6736(11)61267-1PubMedCrossRef

35.

Devroey P, Polyzos NP, Blockeel C: An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011, 26: 2593–2597. 10.1093/humrep/der251PubMedCrossRef

36.

Nelson SM, Lawlor DA: Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. PLoS Med 2011, 8: e1000386. 10.1371/journal.pmed.1000386PubMedCentralPubMedCrossRef

37.

Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J: Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 2003,79(5):1123–1128. 10.1016/S0015-0282(03)00177-8PubMedCrossRef

38.

Papanikolaou EG, Humaidan P, Polyzos N, Kalantaridou S, Kol S, Benadiva C, Tournaye H, Tarlatzis B: New algorithm for OHSS prevention. Reprod Biol Endocrinol 2011, 9: 147. 10.1186/1477-7827-9-147PubMedCentralPubMedCrossRef

39.

Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, Ziebe S, Hald F, Hauge B, Toft B: Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002, 17: 357–361. 10.1093/humrep/17.2.357PubMedCrossRef

40.

Schmidt KL, Ziebe S, Popovic B, Lindhard A, Loft A, Andersen AN: Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil Steril 2001, 75: 337–341. 10.1016/S0015-0282(00)01709-XPubMedCrossRef

Title: Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study
Authors: Stamatina Iliodromiti
Vuong Thi Ngoc Lan
Ho Manh Tuong
Phung Huy Tuan
Peter Humaidan
Scott M Nelson
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2013
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-6-93

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparing long term impact on ovarian reserve between laparoscopic ovarian cystectomy and open laprotomy for ovarian endometrioma

GPER-1 acts as a tumor suppressor in ovarian cancer

ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells